Brighter’s diabetes management devices Actiste® and Actiste® Mini receives market approval in Thailand

Report this content

Brighter AB (publ) is proud to announce that the Actiste® device and the newly developed Actiste® Mini device have received market approval from the Thai FDA, which is a prerequisite to start importing and marketing the products. A cellular transmission approval process, which is a requirement for activation and use of the products, is under way. Further information about Brighter’s commercial plan and strategy for Thailand will follow during the spring.

“We are very pleased to have reached another significant milestone in the commercialization of the Actiste portfolio. This time in Southeast Asia, which is an important region for Brighter. Now remains some additional preparatory work before the time comes for sales, but we believe there is significant potential for our solutions in Thailand,” says Christer Trägårdh, acting CEO of Brighter.

For further information, please contact:

Investor Relations

Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10,,

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 20:30 CET on January 7, 2021.


Documents & Links